Prenatal Genomics Opportunity to engage obstetric clinics and maternal-fetal medicine specialists with Genate prenatal nutrition testing that links 317 SNPs across five metabolic pathways to personalized One-Carbon and Fatty Acid nutrition guidance.

Genetic Testing Advantage Sell the value of gene-guided nutrition to healthcare systems, clinics, and direct-to-consumer channels by highlighting precision nutrition as a differentiator for prenatal care and potential reduction in nutrient deficiency risks.

Clinical Research Basis Position SNP Therapeutics as a research-backed partner by emphasizing its origins in UNC nutrition research and clinical studies, which can support partnerships with academic medical centers and grant-funded programs.

Early Revenue Potential Leverage the Genate launch momentum from early 2024 to pursue pilots with prenatal clinics, nutritionists, and telehealth platforms, aiming for rapid onboarding and case studies that demonstrate measurable outcomes.

Small-Tcap Growth Target strategic collaborations with mid-sized biopharma, nutraceuticals, and precision medicine companies seeking to augment product portfolios with genetic-based nutrition solutions for maternal and fetal health.